Pharsight

Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11827646 GENENTECH INC Compounds for treating spinal muscular atrophy
Jan, 2036

(11 years from now)

US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(14 years from now)

Evrysdi is owned by Genentech Inc.

Evrysdi contains Risdiplam.

Evrysdi has a total of 4 drug patents out of which 0 drug patents have expired.

Evrysdi was authorised for market use on 07 August, 2020.

Evrysdi is available in for solution;oral dosage forms.

Evrysdi can be used as treatment of spinal muscular atrophy.

Drug patent challenges can be filed against Evrysdi from 07 August, 2024.

The generics of Evrysdi are possible to be released after 04 October, 2038.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
Orphan Drug Exclusivity(ODE-400) May 27, 2029
New Patient Population(NPP) May 27, 2025
M(M-270) Oct 03, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents